What are your top takeaways in Hematology from ASCO 2025?

I would say:

1. CARTITUDE-1 updates – first time we are seeing a plateau in a MM trial, that too in the relapsed/refractory setting with 5+ years follow-up.
2. JNJ-5322 Trispecific – dual antigen targeting with less frequent dosing; 100% response rate in BCMA/GPRC5D naïve relapsed/ref MM patients; safety...

The major takeaways:

1. One-third of patients treated with Carvykti on CARTITUDE-1 had not progressed at 5 years.
2. Four drug regimens in the front-line setting lead to high rates of sustained MRD negativity at 1 and 2 years.
3. Peak ALC post Carvykti may be predictive of delayed neurologic toxicity and co...

1. Daver, abstract 6513
2. Terpos, abstract 7512
3. Shadman, abstract 7009

The MD Anderson paper reports early response data that are outstanding, albeit in a very small population. We continue to look for a medication that can improve the poor response rate of HMAs in MDS. If somehow altering macrophage p...

1. 7005 - WaveLINE-003: Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/refractory diffuse large B-cell lymphoma. Interesting study of the ROR1 ADC zilovertamab in R/R DLBCL in combination with R-GEMOX. This, with respect to DL 2 and DL3, demonstrated an improvement in the ef...

Here are a few that I thought were most interesting:

1. 7507 (Long-term follow-up of CARTITUDE-1). While I do think it is premature to conclude that cilta-cel is curative for a portion of patients, this longer-term follow-up shows a subset of patients who have not yet relapsed after 5 years, which doe...